Latest Tokenisation News

Ovanti sharply reduced its quarterly operating cash outflow to A$491,096, helped by higher customer receipts and cost reductions. But with only A$227,000 in cash, the ASX-listed fintech remains dependent on further funding, operating receipts and uncertain legal recoveries.

Klevo Group has reported a sharp FY2026 turnaround, with revenue up 324%, positive operating cash flow and cash rising to A$4.32 million. The more striking claim is its KLVR stablecoin platform, which has recorded USD 59.2 million in unaudited revenue since trial commencement ahead of a planned commercial rollout.

Australian Bond Exchange Holdings improved revenue, reduced its annual loss and sharply cut operating cash outflow in FY2026. Yet with only A$249,000 in cash, net liabilities of A$1.43 million and A$2 million of convertible notes maturing from April 2027, the turnaround remains financially fragile.

Australian Bond Exchange Holdings (ASX: ABE) reported a 47% revenue increase to $3.55 million for FY26, cutting its loss after tax by nearly two-thirds to $1.51 million amid ongoing going concern uncertainty.

Xenitra Limited has secured A$1.5 million through a discounted share placement to accelerate growth in higher-margin OTC medicines, FSMP, and tokenised FMCG sales. The capital will fund inventory expansion, supplier fulfilment, and ecommerce activation as the company shifts from low-margin distribution to a diversified healthcare platform.

Xenitra’s Hong Kong subsidiary Fukang has inked a three-year A$5 million procurement framework for specialised medical nutrition products, broadening its foothold beyond OTC medicines in China’s booming healthcare market.

Xenitra Limited (ASX:XEN) has turned around its cash flow in Q4 FY26, reporting positive operating cash flow of A$0.8 million driven by a leaner cost base and a shift towards higher-margin OTC medicines and blockchain-enabled OPAL tokenised sales.

Xenitra has secured a three-year procurement agreement worth at least A$12 million with Kangsheng, a leading Chinese pharmaceutical distributor, marking its OTC pharmaceuticals division's shift from setup to commercial execution.

I Synergy Group has appointed Anson Heng as Executive Chairman and Managing Director to spearhead its strategic cooperation with Macau Direch, formalised through a non-binding MoU targeting blockchain, AI, and digital asset initiatives.

Xenitra Limited’s OPAL Real World Asset tokenised sales ecosystem has accelerated rapidly, crossing $1.1 million in product sales and onboarding over 400 distribution partners within seven weeks, signalling strong traction in Greater China.

Xenitra Limited has locked in a four-year exclusive distribution agreement for Biomiq Skincare in Greater China, targeting $5 million in minimum purchases and integrating the brand into its blockchain tokenised sales ecosystem.

ASX Limited projects a significant 18-21% rise in expenses for FY27 driven by technology modernisation and regulatory response, while increasing capital expenditure guidance to up to $200 million.